Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.

The paucity of clinical treatment data on rare tumors, such as mesenchymal chondrosarcoma (MCS), emphasizes the need in theranostic tools for these diseases. We put forward and validated a new theranostic method, combining tumor xenografts and mathematical models, and used it to suggest an improved treatment schedule for a particular MCS patient. Growth curves and gene expression analysis of xenografts, derived from a patient's lung metastasis, served for creating a mathematical model of MCS progression and adapting it to the xenograft setting. The pharmacokinetics and pharmacodynamics of six drugs were modeled, with model variables being adjusted by patient-specific chemosensitivity tests. The xenografted animals were treated by various monotherapy and combination schedules, and the MCS xenograft model was computer simulated under the same treatment scenario. The mathematical model for xenograft growth was then up-scaled to retrieve the MCS patient's tumor progression under different treatment schedules. An average accuracy of 87.1% was obtained when comparing model predictions with the observed tumor growth inhibition in the xenografted animals. Simulation results suggested that a regimen containing bevacizumab applied i.v. in combination with once-weekly docetaxel would be more efficacious in the MCS patient than all other simulated schedules. Weekly docetaxel in the patient resulted in stable metastatic disease and relief of pancytopenia due to tumor infiltration. We suggest that the advantage of weekly docetaxel on the triweekly regimen is directly related to the angiogenesis rate of the tumor. Further validation of this conclusion, and the theranostic method we provide, may facilitate personalization of solid cancer pharmacotherapy.

[1]  E. Keshet,et al.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Fagan,et al.  Mesenchymal chondrosarcoma of the head and neck. , 2007, Oral oncology.

[3]  Y. Dor,et al.  Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. , 2001, American journal of physiology. Cell physiology.

[4]  Hui Wang,et al.  Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts , 2004, Clinical Cancer Research.

[5]  M. Milella,et al.  Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. , 2006, Cancer treatment reviews.

[6]  Zvia Agur,et al.  Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. , 2006, Cancer research.

[7]  Z. Agur,et al.  Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. , 2005, European journal of cancer.

[8]  L B Sheiner,et al.  Pharmacokinetic and pharmacodynamic modeling in vivo. , 1981, Critical reviews in bioengineering.

[9]  Z. Agur,et al.  The growth law of primary breast cancer as inferred from mammography screening trials data. , 1998, British Journal of Cancer.

[10]  M. Karamouzis,et al.  In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. , 2004, Seminars in oncology.

[11]  Zvia Agur,et al.  New TPO treatment schedules of increased safety and efficacy: pre‐clinical validation of a thrombopoiesis simulation model , 2003, British journal of haematology.

[12]  H. Hammes,et al.  Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. , 2004, Diabetes.

[13]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[14]  Z. Agur,et al.  Bone marrow regeneration under cytotoxic drug regimens: behaviour ranging from homeostasis to unpredictability in a model for hemopoietic differentiation. , 1992, Bio Systems.

[15]  U. Schlötzer-Schrehardt,et al.  Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation , 2003, The British journal of ophthalmology.

[16]  R. Danesi,et al.  A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed , 2004, Clinical Cancer Research.

[17]  W. D. Daniels,et al.  Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Z. Agur,et al.  A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth , 2004, Angiogenesis.

[19]  S. Zeng,et al.  Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. , 2004, Acta pharmacologica Sinica.

[20]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[21]  T. Danielsen,et al.  The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts , 2000, British Journal of Cancer.

[22]  Luigi Preziosi,et al.  Cancer Modelling and Simulation , 2003 .

[23]  P Ubezio,et al.  Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. , 1994, Cancer research.

[24]  Zvia Agur,et al.  Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency , 2004, Cancer Chemotherapy and Pharmacology.

[25]  L. Weisenthal,et al.  Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. , 1983, Cancer research.

[26]  Peteris Daugulis,et al.  Chapter 7 Multi-Scale Analysis of Angiogenic Dynamics and Therapy , 2003 .

[27]  O. Féron.  Targeting the tumor vascular compartment to improve conventional cancer therapy. , 2004, Trends in pharmacological sciences.

[28]  P K Maini,et al.  A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results , 2005, Bulletin of mathematical biology.

[29]  W F Ebling,et al.  Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? , 1996, Journal of pharmaceutical sciences.

[30]  Peteris Daugulis,et al.  Hopf point analysis for angiogenesis models , 2003 .

[31]  H. Hammes,et al.  Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression , 2006, Thrombosis and Haemostasis.

[32]  S. Gad.  Preclinical development handbook ; ADME and biopharmaceutical properties , 2008 .

[33]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[34]  G. Breier,et al.  Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells (*) , 1995, The Journal of Biological Chemistry.

[35]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[36]  K. Unni,et al.  Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases , 1986, Cancer.

[37]  G. Peters,et al.  Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. , 2000, European Journal of Cancer.

[38]  G. Bonadonna,et al.  Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Yusuke Nakamura,et al.  Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. , 2002, Cancer research.

[40]  Dirk P. Kroese,et al.  The Cross-Entropy Method for Continuous Multi-Extremal Optimization , 2006 .

[41]  Yuri Kogan,et al.  Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics , 2008 .

[42]  Z. Agur,et al.  Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. , 1992, European journal of cancer.

[43]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[44]  R. Kallman.  Rodent tumor models in experimental cancer therapy , 1987 .

[45]  Zvia Agur,et al.  Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs , 1988 .

[46]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[47]  Z. Agur,et al.  Use of mathematical models for understanding the dynamics of gene amplification. , 1993, Mutation research.

[48]  H. Lenz,et al.  Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. , 2006, Clinical colorectal cancer.

[49]  F. Peale,et al.  Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.

[50]  S. Thorgeirsson,et al.  Rapid determination of DNA synthesis in adherent cells grown in microtiter plates. , 1985, Experimental cell research.

[51]  T. Shimada,et al.  Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice , 2005, The Journal of pharmacy and pharmacology.

[52]  Zvia Agur,et al.  USING COMPUTER SIMULATIONS FOR EVALUATING THE EFFICACY OF BREAST CANCER CHEMOTHERAPY PROTOCOLS , 1999 .

[53]  Z. Agur,et al.  Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study , 2010 .

[54]  M. Marty,et al.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.

[55]  Z. Agur,et al.  The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. , 2005, Journal of theoretical biology.

[56]  M. Highley,et al.  The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors , 2002, Anti-cancer drugs.

[57]  M. Chambers,et al.  A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. , 2004, Seminars in oncology.

[58]  Z. Agur,et al.  Resonance and Anti-Resonance in the Design of Chemotherapeutic Protocols , 1998 .

[59]  P. Picci,et al.  Mesenchymal chondrosarcoma of bone and soft tissues , 1983, Cancer.